Mycotoxin biosynthesis inhibitors for fusarium head blight control in cereals

Overview

Fusarium Head Blight (FHB) is a destructive fungal disease affecting cereals and maize, producing heat-stable type B trichothecene mycotoxins (TCTB) that persist through food processing and pose health risks to humans and livestock. Current regulatory limits for these toxins in wheat, durum wheat, and maize make pre-harvest prevention critical. This research delivers two promising small-molecule inhibitors, M1 and M2, identified through computational docking of over 10,240 molecules against three validated fungal targets. In vitro assays confirmed significant suppression of TCTB biosynthesis, positioning these compounds as potential field-applied solutions to limit mycotoxin contamination at the cultivation stage.

Technical specifications

Research approach:

• Structure-based drug design combined with in vitro validation against key fungal enzyme targets
• Three molecular targets identified: endoglucanase-5, trichodiene synthase (TRI5), and 24-sterol C-methyltransferase (ERG6)
• 10,240 molecules computationally docked, narrowed to 15 putative inhibitors
• Two lead compounds selected for experimental validation: M1 (tested at 50 and 150 µM) and M2 (tested at 5 and 15 µM)

Key results:

• M1 at 50 µM achieved approximately 28% inhibition of TCTB biosynthesis
• M1 at 150 µM achieved approximately 56% inhibition of TCTB biosynthesis
• M1 demonstrated consistent efficacy across most tested Fusarium graminearum and F. culmorum strains
• Validation performed across 8 Fusarium strains

Proposed next steps:

• Extend testing to structural analogs selected based on Tanimoto similarity coefficients
• Integrate nanotechnology approaches to enhance delivery and specificity
• Scale up validation toward potential field application for reducing Fusarium damage in grain storage

Technology readiness level

The inhibitors are currently at an early-to-mid stage of development. In silico screening and initial in vitro assays have been completed, demonstrating proof-of-concept efficacy for M1 as a TCTB biosynthesis inhibitor. Further experimental validation with analogs and larger-scale testing are needed before field deployment. The research team is seeking partnerships to advance compound optimization, delivery formulation, and scale-up validation toward a cost-effective, low-risk agricultural product for mycotoxin prevention.